Non-Hodgkin's Lymphoma Incidence
In epidemiology, "incidence rate" is a measure of how many people within a given population will develop a disease or other condition during a specified period of time. It is, essentially, a measurement of risk.
The National Cancer Institute estimates that 65,980 new cases of Non-Hodgkin's Lymphoma will be diagnosed in 2009. This represents 89% of all lymphomas, and 4% of all cancers diagnosed. It is the seventh most common cancer in the United States.
According to the Leukemia and Lymphoma Society:
- The chance of developing Non-Hodgkin's Lymphoma during your lifetime is 1 in 50, or 2%. However, this percentage increases if you have one or more risk factors for the disease.
- NHL is more prevalent in males than females–55% of lymphoma diagnoses are for male patients
- Of those diagnosed with the disease, 95% are adults and 5% are children
- It is more prevalent in patients over the age of 60
- The average age at diagnosis is 65
- Due to aging of the "baby boom" population, the incidence of NHL is expected to rise in the coming years
Lymphoma is a well-researched subject and many statistics are published annually. For the most up-to-date and complete statistical information on lymphoma, please see the resources listed at the bottom of the page.
Lymphoma statistics resources
Related Articles
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
